Bio-Rad Laboratories Class A
241 hedge funds and large institutions have $3.05B invested in Bio-Rad Laboratories Class A in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 81 increasing their positions, 89 reducing their positions, and 22 closing their positions.
592% more call options, than puts
Call options by funds: $5.99M | Put options by funds: $866K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
11% more capital invested
Capital invested by funds: $2.74B → $3.05B (+$314M)
2% more funds holding
Funds holding: 236 → 241 (+5)
0.18% less ownership
Funds ownership: 78.78% → 78.6% (-0.18%)
9% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 89
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$45.5M |
| 2 |
LHC
Lodge Hill Capital
New York
|
+$19.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$13.3M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$9.56M |
| 5 |
Millennium Management
New York
|
+$9.36M |
Top Sellers
| 1 |
LCS
Levin Capital Strategies
New York
|
-$63.4M |
| 2 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$16.9M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$7.63M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$5.62M |
| 5 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
-$4.99M |
BIO Hedge Fund Activity: Q3 2016 in Review
241 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2016, worth a combined $3.05B — up 11% from $2.74B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BIO positions and 22 closed out — a net gain of 7 holders — while 81 added to existing stakes and 89 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $45.5M. The largest seller was Levin Capital Strategies, cutting an estimated $63.4M.
- 241 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2016, up from 236 in Q2 2016.
- Funds reported $3.05B of Bio-Rad Laboratories Class A stock for Q3 2016, up 11% quarter-over-quarter.
- 29 funds opened new Bio-Rad Laboratories Class A positions in Q3 2016 and 22 closed out, a net change of +7 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q3 2016 was Morgan Stanley, an estimated $45.5M added.
- The largest Bio-Rad Laboratories Class A seller in Q3 2016 was Levin Capital Strategies, an estimated $63.4M sold.
Based on aggregated 13F filings for Q3 2016.